Comparative efficacy of oral and intravenous macrolide antibiotics in treating pediatric pneumonia caused by Mycoplasma pneumoniae  

口服与静脉大环内酯类抗菌药在治疗肺炎支原体引发的儿科肺炎中的疗效比较

作　　者：Lirong Qian Lina Gao 钱利荣;高丽娜(浙江中医药大学,浙江杭州310053;杭州市第九人民医院儿科,浙江杭州311225)

机构地区：[1]Zhejiang University of Traditional Chinese Medicine,Hangzhou 310053,Zhejiang,China [2]Department of Pediatrics,Hangzhou Ninth People's Hospital,Hangzhou 311225,Zhejiang,China

出　　处：《Journal of Chinese Pharmaceutical Sciences》2024年第12期1146-1152,共7页中国药学(英文版)

摘　　要：To evaluate the clinical efficacy and safety of oral versus intravenous macrolide antibacterials in managing pediatric pneumonia attributable to Mycoplasma pneumoniae(MP),we conducted a retrospective analysis of clinical data from 100 pediatric patients treated in our pediatric outpatient and inpatient departments between January 2020 and August 2023.These patients were divided into two groups based on the method of antibiotic administration:one oral group(n=50)and one intravenous group(n=50).The oral group received either azithromycin or clarithromycin,while the intravenous group received azithromycin or roxithromycin,both at a dosage of 10 mg/kg/d,for a continuous treatment duration of 3-7 d.We compared various clinical parameters,including clinical features,body temperature,white blood cell count,C-reactive protein levels,improvement in chest radiography,recovery time,overall efficacy rate,and incidence of adverse reactions before and after treatment in both groups.Our results reveal ed no statistically significant differences in clinical features,laboratory test results,or chest radiographic manifestations between the two groups before treatment(P>0.05).Following treatment,significant reductions in body temperature,white blood cell count,and C-reactive protein levels were observed in both groups.Additionally,chest radiographic improvement was noted in 100%of cases,with shortened recovery times and an overall efficacy rate of 100%,demonstrating no significant difference between the groups(P>0.05).The incidence of adverse reactions was 6%in the oral group and 8%in the intravenous group,primarily consisting of mild gastrointestinal reactions.No severe adverse reactions were reported,and the difference in incidence between the groups was not statistically significant(P>0.05).Our study underscored the comparable clinical efficacy and safety of oral and intravenous macrolide antibiotics in treating pediatric pneumonia caused by MP.Considering its convenience and cost-effectiveness,oral administration emerged as a f本研究旨在比较口服与静脉大环内酯类抗菌药在治疗肺炎支原体引发的儿科肺炎中的临床疗效和安全性。回顾性分析2020年1月至2023年8月我院儿科门诊和病房诊治的100例肺炎支原体肺炎患儿的临床资料,根据抗菌药物给药方式分为口服组(n=50)和静脉组(n=50),口服组给予阿奇霉素或克拉霉素,静脉组给予阿奇霉素或罗红霉素,两组均按10mg/kg/d剂量,连续治疗3–7天。比较两组患儿的临床特征、治疗前后的体温、白细胞计数、C反应蛋白、胸部影像学改善情况、恢复时间、总有效率和不良反应发生率。结果显示两组患儿在治疗前的临床特征、实验室检查和胸部影像学表现无统计学差异(P>0.05)。治疗后,两组患儿的体温、白细胞计数、C反应蛋白均明显下降,胸部影像学改善率均达到100%,恢复时间均缩短,总有效率均达到100%,差异均无统计学意义(P>0.05)。两组患儿的不良反应发生率分别为6%和8%,主要为轻度胃肠道反应,无严重不良反应发生,差异无统计学意义(P>0.05)。本研究说明口服与静脉大环内酯类抗菌药在治疗肺炎支原体引发的儿科肺炎中具有相似的临床疗效和安全性,口服给药方式更便捷、经济,可作为首选治疗方案。

关 键 词：Mycoplasma pneumoniae PNEUMONIA PEDIATRICS MACROLIDES ANTIBACTERIAL 

分 类 号：R961[医药卫生—药理学]